Back in busi­ness af­ter a spell in lim­bo, Iron­shore says it has raised $143M for AD­HD drug roll­out

It looks like Iron­shore Phar­ma­ceu­ti­cals is back in busi­ness.

Sev­en months af­ter the com­pa­ny shut­tered its com­mer­cial ops as its new drug ap­pli­ca­tion for a re­for­mu­la­tion of methylphenidate to treat AD­HD drift­ed in­to lim­bo, the com­pa­ny says that it was green-light­ed by the FDA. And now it’s an­nounced $143 mil­lion in fi­nanc­ing to launch the drug, to be mar­ket­ed as Jor­nay.

There’s noth­ing new about its drug, methylphenidate. That’s the ac­tive in­gre­di­ent in Ri­tal­in and oth­er gener­ic stim­u­lants used to treat AD­HD. Iron­shore de­vel­oped this ver­sion of the drug us­ing some de­layed-re­lease tech that it hopes will dis­tin­guish it from the crowd.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER